الفهرس 
LIST OF TABLESOnly 14 pages are availabe for public view
 |  | from | 355 |  |  |
| | | from | 355 | | |
Abstract
Therapeutic effectiveness of a drug depends upon the bioavailability
and ultimately upon the solubility of drug molecules. Solubility is one of
the important parameter to achieve desired concentration of drug in
systemic circulation for pharmacological response to be shown. Currently
only 8% of new drug candidates have both high solubility and
permeability.
The objective of work in this thesis is to compare three different
techniques used to enhance solubility and bioavailability using
glibenclamide as a model of poorly water soluble drug.
Glibenclamide (GBM) is a second-generation sulfonylurea oral
hypoglycemic agent used in the treatment of non insulin dependent
diabetes mellitus. It causes hypoglycemia by stimulating release of insulin
from pancreatic cells and by increasing the sensitivity of peripheral tissue
to insulin.
Thus the work in this thesis is divided into four chapters:
Chapter I: Enhancement of the solubility of glibenclamide by lyophilized
dry emulsion technique
Chapter II: Enhancement of the solubility of glibenclamide by surface
solid dispersion technique
Chapter III: Enhancement of the solubility of glibenclamide by liquisolid
technique
Chapter IV: Bioequivalence study of the selected glibenclamide
formulations
CHAPTER I
Enhancement of the solubility of glibenclamide by lyophilized dry emulsion
technique
The aim of work in this chapter to enhance the solubility of
glibenclamide using lyophilized dry emulsion technique.
Eight formulae, each containing glibenclamide (5 mg/tablet) were
proposed adopting a factorial design (23), in which three factors were
tested. They were namely, type of surfactant (x1), type of oil (x2), and type
of carrier (x3).
Two types of surfactants were chosen; Tween 80 (low level (-1)) and
Cremophor EL (high level (+1)). The oils were sesame oil (low level (-1))
and miglyol 812 (high level (+1)). Finally, carriers were lactose
monohydrate (low level (+1)) and maltodextrin (high level (+1)). The
lyophilized dry emulsion (LDE) tablets were obtained by freeze-drying the
emulsions (o/w) containing GBM. The prepared emulsions prior.